New England Journal of Medicine· 2013Q1

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

Daniel D. Von Hoff, Thomas J. Ervin, Francis P. Arena, E. Gabriela Chiorean et al.

6,697citations
Q1SCImago
2013year

Short summary

Adding nab-paclitaxel to gemcitabine significantly improved median overall survival by 1.8 months (8.5 vs. 6.7 months) in patients with metastatic pancreatic cancer, according to a phase 3 trial (n=861).

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Oncology

OncologyMedicine